$ADVM
Adverum Biotechnologies, Inc.

2017 Q2 Form 10-Q Financial Statement

#000156459017016588 Filed on August 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q4 2016 Q2
Revenue $463.0K $488.0K $307.0K
YoY Change 50.81% -49.17% 51.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.060M $4.780M $5.110M
YoY Change -20.55% -10.99% 3.02%
% of Gross Profit
Research & Development $8.490M $7.900M $7.960M
YoY Change 6.66% -4.13% 55.29%
% of Gross Profit
Depreciation & Amortization $540.0K $480.0K $340.0K
YoY Change 58.82% 60.0% 126.67%
% of Gross Profit
Operating Expenses $12.56M $23.88M $62.19M
YoY Change -79.81% 57.71% 516.65%
Operating Profit -$12.09M -$61.88M
YoY Change -80.46% 526.21%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $663.0K $220.0K $222.0K
YoY Change 198.65% 144.44% 91.38%
Pretax Income -$11.43M -$23.17M -$61.66M
YoY Change -81.46% 64.44% 531.12%
Income Tax -$780.0K
% Of Pretax Income
Net Earnings -$11.43M -$22.39M -$61.66M
YoY Change -81.46% 58.89% 531.37%
Net Earnings / Revenue -2468.68% -4588.93% -20084.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$265.8K -$535.1K -$1.760M
COMMON SHARES
Basic Shares Outstanding 41.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q4 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $197.4M $222.2M $241.3M
YoY Change -18.19% -14.24% -13.7%
Cash & Equivalents $39.52M $222.2M $241.3M
Short-Term Investments $157.9M $0.00
Other Short-Term Assets $2.200M $2.200M $1.200M
YoY Change 83.33% 46.67% 20.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $199.6M $225.3M $243.6M
YoY Change -18.06% -13.69% -13.2%
LONG-TERM ASSETS
Property, Plant & Equipment $3.800M $4.169M $4.000M
YoY Change -5.0% 30.81% 35.82%
Goodwill
YoY Change
Intangibles $5.000M $16.65M
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $140.0K $100.0K
YoY Change 0.0% 0.0% -27.54%
Total Long-Term Assets $9.000M $9.309M $20.70M
YoY Change -56.52% 179.8% 571.42%
TOTAL ASSETS
Total Short-Term Assets $199.6M $225.3M $243.6M
Total Long-Term Assets $9.000M $9.309M $20.70M
Total Assets $208.6M $234.6M $264.3M
YoY Change -21.07% -11.25% -6.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $1.474M $2.400M
YoY Change -54.17% 143.64% 26.58%
Accrued Expenses $5.200M $6.500M $4.100M
YoY Change 26.83% 62.5% 13.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.300M $9.896M $7.900M
YoY Change 5.06% 50.53% 0.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.800M $386.0K $6.700M
YoY Change 1.49% -92.58% 28.85%
Total Long-Term Liabilities $6.800M $386.0K $6.700M
YoY Change 1.49% -92.58% 28.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.300M $9.896M $7.900M
Total Long-Term Liabilities $6.800M $386.0K $6.700M
Total Liabilities $16.40M $18.98M $16.69M
YoY Change -1.74% 61.87% 27.52%
SHAREHOLDERS EQUITY
Retained Earnings -$197.9M -$161.2M
YoY Change 135.14% 187.94%
Common Stock $413.5M $408.9M
YoY Change 22.79% 25.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $192.2M $215.6M $247.7M
YoY Change
Total Liabilities & Shareholders Equity $208.6M $234.6M $264.3M
YoY Change -21.1% -11.25% -6.83%

Cashflow Statement

Concept 2017 Q2 2016 Q4 2016 Q2
OPERATING ACTIVITIES
Net Income -$11.43M -$22.39M -$61.66M
YoY Change -81.46% 58.89% 531.37%
Depreciation, Depletion And Amortization $540.0K $480.0K $340.0K
YoY Change 58.82% 60.0% 126.67%
Cash From Operating Activities -$11.42M -$8.350M -$8.230M
YoY Change 38.76% -8.54% -11.03%
INVESTING ACTIVITIES
Capital Expenditures -$470.0K -$920.0K -$1.010M
YoY Change -53.47% 384.21% -6.48%
Acquisitions
YoY Change
Other Investing Activities -$20.20M $0.00 $3.450M
YoY Change -685.51% -100.0% -61.24%
Cash From Investing Activities -$20.67M -$920.0K $2.440M
YoY Change -947.13% -103.06% -68.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 150.0K 210.0K 90.00K
YoY Change 66.67% -175.0% -18.18%
NET CHANGE
Cash From Operating Activities -11.42M -8.350M -8.230M
Cash From Investing Activities -20.67M -920.0K 2.440M
Cash From Financing Activities 150.0K 210.0K 90.00K
Net Change In Cash -31.94M -9.060M -5.700M
YoY Change 460.35% -143.87% 335.11%
FREE CASH FLOW
Cash From Operating Activities -$11.42M -$8.350M -$8.230M
Capital Expenditures -$470.0K -$920.0K -$1.010M
Free Cash Flow -$10.95M -$7.430M -$7.220M
YoY Change 51.66% -16.89% -11.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
172788000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3449000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
342000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-231000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-182647000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221348000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
64845000
advm Fixed Assets In Accounts Payable Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
124000
advm Fixed Assets In Accounts Payable Accrued Expenses And Other Current Liabilities
FixedAssetsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilities
153000
CY2017Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
463000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-77390000
CY2016Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
49120000
us-gaap Net Income Loss
NetIncomeLoss
-27529000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
49120000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12093000
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
307000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
925000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-61882000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1152000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
222000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
663000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
338000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
10000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
572000
us-gaap Operating Expenses
OperatingExpenses
29606000
us-gaap Operating Expenses
OperatingExpenses
77962000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28681000
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234583000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41805009
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43201786
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41805009
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
215600000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
208579000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17553000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
62189000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13432000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15410000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5114000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
12556000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12053000
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43201786
us-gaap Net Income Loss
NetIncomeLoss
-77052000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
338000
CY2017Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-49000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1069000
advm Amortization Of Premium And Accrued Interest On Marketable Securities
AmortizationOfPremiumAndAccruedInterestOnMarketableSecurities
203000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
24000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
580000
us-gaap Straight Line Rent
StraightLineRent
27000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37738000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-988000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1575000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20377000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1126000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
40061000
CY2017Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
37289000
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
158032000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-11
CY2017Q2 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
37289000
CY2017Q2 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
138000
CY2017Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
157895000
CY2017Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
160946000
CY2017Q2 advm Available For Sale Securities Debt Maturities After Year One Through Three Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesAfterYearOneThroughThreeAmortizedCostBasis
34375000
CY2017Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
195321000
CY2017Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
160870000
CY2017Q2 advm Available For Sale Securities Debt Maturities After Year One Through Three Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterYearOneThroughThreeFairValue
34314000
CY2017Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
195184000
CY2017Q2 advm Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Temporary
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxTemporary
100000
CY2017Q2 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0
CY2017Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2017Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
195184000
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7442000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6763000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3644000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2594000
CY2017Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2016Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2017Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1363000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2570000
CY2017Q2 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
676000
CY2016Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
1683000
CY2017Q2 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
424000
CY2016Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
1142000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
501000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
894000
CY2017Q2 advm Accrued Contract Settlement
AccruedContractSettlement
2000000
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
262000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
162000
us-gaap Lessor Leasing Arrangements Operating Leases Renewal Term
LessorLeasingArrangementsOperatingLeasesRenewalTerm
P4Y
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-08
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2017Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
1
CY2017Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
13000000
advm Share Based Compensation Arrangement By Share Based Payment Award Options Difference Between Options Exercise Price And Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDifferenceBetweenOptionsExercisePriceAndClosingPriceOfCommonStockIntrinsicValueAmount
2.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6300000
CY2017Q2 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
2243000
CY2016Q2 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
2826000
advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
4139000
advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
6910000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
2500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
2
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9900000

Files In Submission

Name View Source Status
0001564590-17-016588-index-headers.html Edgar Link pending
0001564590-17-016588-index.html Edgar Link pending
0001564590-17-016588.txt Edgar Link pending
0001564590-17-016588-xbrl.zip Edgar Link pending
advm-10q_20170630.htm Edgar Link pending
advm-20170630.xml Edgar Link completed
advm-20170630.xsd Edgar Link pending
advm-20170630_cal.xml Edgar Link unprocessable
advm-20170630_def.xml Edgar Link unprocessable
advm-20170630_lab.xml Edgar Link unprocessable
advm-20170630_pre.xml Edgar Link unprocessable
advm-ex311_7.htm Edgar Link pending
advm-ex312_6.htm Edgar Link pending
advm-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending